First, many of the previous results can be now appreciated in finer detail, such as (a) the reduction in number of coactivated driver-target pairs in MS, (b) the large number of targets that can be controlled by SOCS1 and SOCS3, and (c) the potential of NFKB1, IFNA1, and IFNB1 to affect the driver-target functional interactions. This evidence concerns the gene IFNA1 and myeloid sarcoma.